Bacterial Encephalitis Among Malnourished Children: A Growing Silent Threat

 

  Encephalitis

Encephalitis refers to inflammation of the brain tissue, most commonly caused by infections. While viruses are the leading cause, bacterial encephalitis—though less common—is often more severe and life-threatening. When it occurs in malnourished children, the consequences can be devastating due to their weakened immune systems

Malnutrition and infection form a vicious cycle. A malnourished child is more susceptible to infections, and infections further worsen nutritional status. In regions like South Asia and Sub-Saharan Africa, where malnutrition remains prevalent, bacterial encephalitis is an under-recognized yet critical health issue.

Understanding Malnutrition in Children

Malnutrition refers to deficiencies, excesses, or imbalances in a child’s intake of energy and nutrients. In the context of encephalitis, undernutrition is most relevant.

Types of Malnutrition:

• Wasting (Acute malnutrition): Low weight for height
• Stunting (Chronic malnutrition): Low height for age
• Underweight: Low weight for age
• Micronutrient deficiencies: Lack of vitamins and minerals like Vitamin A, Zinc, Iron

Why Malnutrition Matters:

Malnutrition weakens:

• Immune system
• Barrier defenses (skin, mucosa)
• Brain development

This makes children more vulnerable to severe infections, including bacterial invasion of the central nervous system.

 Causes of Bacterial Encephalitis

Bacterial encephalitis is usually caused by pathogens that either directly infect brain tissue or spread from nearby infections (like meningitis).

Common Causative Bacteria:

• Streptococcus pneumoniae
• Neisseria meningitidis
• Haemophilus influenzae type b (Hib)
• Listeria monocytogenes
• Escherichia coli (especially in neonates)

Routes of Infection:

1. Hematogenous spread: Bacteria enter bloodstream and reach brain
2. Direct spread: From ear, sinus, or skull infections
3. Trauma or surgery: Breach in protective barriers

Why Malnourished Children Are at Higher Risk

Malnourished children face a significantly higher risk of bacterial encephalitis due to multiple biological and social factors:

1. Weak Immune Response

• Reduced production of antibodies
• Impaired white blood cell function
• Poor inflammatory response

2. Compromised Blood-Brain Barrier

Malnutrition can weaken the blood-brain barrier, allowing pathogens easier access to brain tissue.

3. Co-existing Infections

Malnourished children often suffer from:

• Diarrhea
• Pneumonia
• Tuberculosis

These infections can increase the risk of systemic bacterial spread.

4. Delayed Healthcare Access

In many rural or impoverished settings:

• Parents may delay seeking care
• Lack of awareness worsens outcomes

 Clinical Features (Symptoms)

5

Symptoms of bacterial encephalitis can progress rapidly and may overlap with meningitis.

Early Symptoms:

• High fever
• Irritability
• Poor feeding
• Vomiting

Neurological Signs:

• Seizures
• Altered consciousness
• Confusion or lethargy
• Neck stiffness
• Sensitivity to light

Severe Complications:

• Coma
• Brain swelling
• Paralysis
• Death

In malnourished children, symptoms may be atypical or less pronounced, making diagnosis more difficult.

Diagnosis

Early diagnosis is crucial but challenging in resource-limited settings.

Key Diagnostic Methods:

• Lumbar puncture (CSF analysis)
• Blood cultures
• Neuroimaging (CT/MRI)
• PCR testing for pathogens

Challenges:

• Lack of diagnostic facilities
• Delayed presentation
• Overlapping symptoms with other diseases

Treatment and Management

Bacterial encephalitis is a medical emergency requiring immediate intervention.

1. Antibiotic Therapy

• Broad-spectrum antibiotics started immediately
• Later tailored based on culture results

2. Supportive Care

• Oxygen therapy
• Fluid management
• Anti-seizure medications

3. Nutritional Rehabilitation

For malnourished children:

• Therapeutic feeding (e.g., RUTF)
• Micronutrient supplementation
• Gradual nutritional recovery

4. Intensive Care

Severe cases may require:

• Mechanical ventilation
• Monitoring of brain pressure

Complications

Even with treatment, many children suffer long-term consequences:

• Cognitive impairment
• Learning disabilities
• Hearing loss
• Epilepsy
• Behavioral issues

Malnutrition worsens these outcomes due to impaired brain recovery.

 Public Health Perspective

Bacterial encephalitis in malnourished children is not just a medical issue—it is a social and economic problem.

Key Risk Factors:

• Poverty
• Poor sanitation
• Lack of vaccination
• Inadequate nutrition

High-Burden Regions:

• South Asia (including Nepal, India)
• Sub-Saharan Africa

Prevention Strategies

Prevention is the most effective strategy to reduce the burden.

1. Immunization

Vaccines against:

• Hib
• Pneumococcus
• Meningococcus

These significantly reduce bacterial infections leading to encephalitis.

2. Improving Nutrition

• Exclusive breastfeeding (first 6 months)
• Balanced diet
• Micronutrient supplementation

3. Hygiene and Sanitation

• Clean water
• Handwashing
• Safe food practices

4. Early Detection

• Community awareness
• Training healthcare workers

The Vicious Cycle: Malnutrition and Infection

Malnutrition and infection reinforce each other:

• Malnutrition → weak immunity → infection
• Infection → poor appetite → nutrient loss → worsened malnutrition

Breaking this cycle is essential to prevent diseases like encephalitis.

 Future Directions

Research Needs:

• Better diagnostic tools for rural settings
• Affordable treatments
• Nutritional interventions during infection

Policy Actions:

• Strengthening primary healthcare
• Expanding immunization programs
• Addressing poverty and food insecurity

Conclusion

Bacterial encephalitis among malnourished children is a serious yet preventable condition. It highlights the intersection of infection, nutrition, and socio-economic factors. While medical treatment is critical, long-term solutions lie in improving nutrition, ensuring vaccination, and strengthening healthcare systems.

Every child deserves a healthy start to life. Addressing malnutrition is not just about food—it is about protecting children from life-threatening diseases like encephalitis and ensuring their cognitive and physical development.

Understanding Bacterial Infections in Women and Gallbladder Stones: Causes, Symptoms, Treatment, and Prevention

Dealing with health problems, especially internal infections or organ complications, often feels overwhelming. For many women, two common concerns stand out: bacterial infections and gallbladder stones. They’re quite different—one’s mostly about infections, the other about organ function—but both need attention and care to avoid bigger issues. Let’s break down both topics in detail, looking at what causes them, typical symptoms, how doctors diagnose them, options for treatment, and ways to prevent them.

 Part 1: Bacterial Infections in Women

 Bacterial infections are a widespread problem among women, mainly because harmful bacteria manage to enter the body, multiply, and throw things out of balance. Women have unique risks for some types of bacterial infections due to anatomy and hormones.

 Common Types of Bacterial Infections in Women

 The main players in this category:

•  Urinary tract infections (UTIs)
• Bacterial vaginosis (BV)
• Pelvic inflammatory disease (PID)
• Sexually transmitted infections (STIs) like chlamydia and gonorrhea

 Each one targets a different part of the reproductive or urinary system, and severity varies.

 Causes and Risk Factors

 There are several reasons why bacterial infections pop up:

•  Poor hygiene
• Unprotected sex
• Hormonal shifts
• Weak immune system
• Using certain contraceptives, like diaphragms
• Long-term antibiotics that disturb natural flora

 UTIs, for example, start when bacteria from the digestive tract find their way into the urinary system. BV happens if the balance of vaginal bacteria gets tipped.

 Symptoms to Watch For

 Symptoms depend on the infection but might include:

•  Pain or burning during urination
• Odd-smelling or unusual vaginal discharge
• Pelvic pain
• Fever and general fatigue
• Discomfort during intercourse
• Frequent need to urinate

 

If left unchecked, these issues—especially PID—can seriously affect fertility.

 Diagnosis

 Doctors use simple tests:

•  Urine sample
• Vaginal swab
• Blood work
• Pelvic exam

 Quick diagnosis stops things from getting worse.

 Treatment Options

 Antibiotics usually solve the problem. Type and duration depend on which infection you have:

•  UTIs: Short course of oral antibiotics
• BV: Antibiotic gels or pills
• STIs: Tailored antibiotic treatment for both partners

 Finish the whole course, even if you start feeling better before it’s done.

 Prevention Tips

•  Good hygiene and healthy routines matter:
• Hydrate well
• Practice safe sex
• Skip harsh soaps or douches
• Wear breathable, cotton underwear
• Wipe from front to back after the toilet
•  Regular gynecological visits catch problems early.

 

Part 2: Gallbladder Stones (Gallstones)

 Gallstones are hardened bits of digestive fluid that collect in the gallbladder—a small organ tucked beneath your liver that helps digest fat.

 What Causes Gallstones?

 Gallstones form when there’s a mix-up in the bile:

•  Too much cholesterol
• Excess bilirubin
• Gallbladder doesn’t empty well

 Types include:

•  Cholesterol stones (most common)
• Pigment stones (made of bilirubin)

 Risk Factors

 Certain things make gallstones more likely:

•  Being female
• Obesity
• Diet high in fat or cholesterol
• Rapid weight loss
• Pregnancy
• Diabetes
• Family history

 Estrogen boosts cholesterol in bile, so women are more prone to gallstones.

 Symptoms of Gallstones

 Many people won’t notice any symptoms at first. When they do show up, though, they can be pretty severe:

•  Sudden pain in the upper right abdomen
• Pain after eating fatty meals
• Nausea, vomiting
• Pain between shoulder blades or in the back
• Indigestion, bloating

 When a stone blocks a bile duct, pain gets intense—a classic gallbladder attack.

 Complications

 Untreated gallstones can lead to:

•  Gallbladder inflammation
• Bile duct blockage
• Pancreatitis
• Organ infection

 Sometimes these call for emergency medical help.

 Diagnosis

 Doctors rely on a few key tests:

•  Ultrasound (most common)
• CT scan
• Blood tests

MRI if things look complicated

 The sooner you know, the easier it is to avoid complications.

 Treatment Options

 Options depend on how bad the symptoms are:

 1. Medications

 Some drugs can dissolve cholesterol stones, but it’s slow and doesn’t always work.

 2. Surgery

 Gallbladder removal (cholecystectomy) is the most effective option. Usually done laparoscopically—quick recovery.

 3. Lifestyle Management

 For mild cases, diet and lifestyle changes might be enough.

 Diet and Lifestyle Tips

 Reduce your risk by:

•  Maintaining healthy weight
• Avoiding rapid weight drops
• Eating more fiber
• Cutting back on fatty and fried foods
• Exercising regularly
•  Good foods include fruits, veggies, whole grains, lean proteins.

 Connection Between Bacterial Infections and Gallstones

 Although these problems are separate, sometimes they intersect:

•  Gallstones can lead to gallbladder infections (cholecystitis)
• Bacterial infections develop in bile ducts if blocked
• Chronic infections can weaken immunity and affect digestion

 Rarely, bacteria actually help form pigment gallstones.

 

When to See a Doctor

 Don’t wait if you experience:

•  Long-lasting abdominal pain
• High fever and chills
• Yellowing skin or eyes (jaundice)
• Strong urinary or vaginal symptoms

 Acting early prevents complications and leads to better outcomes.

 

Final Thoughts

 Bacterial infections in women and gallbladder stones are common—but manageable. Paying attention to symptoms, getting diagnosed early, and following through with treatment are key for staying healthy. While antibiotics usually handle bacterial infections, gallstones might need surgery if things get serious.

 Healthy habits, good hygiene, and regular check-ups make a real difference. Listen to your body—it’ll let you know when something’s off. Taking action can keep problems from growing.

 By understanding these issues, women can make smart choices and stay ahead when it comes to their health.

The Use of AI in Identifying Pathogenic Organisms in Pharmaceutical Settings

Pharma’s a tough business. There’s strict oversight, and accuracy matters a lot—especially when it comes to spotting dangerous microbes. If bacteria, fungi, or viruses sneak into the mix, drugs can become unsafe, production stalls, and, honestly, people’s health is put on the line. For ages, labs used culture-based techniques, manual biochemical tests, and the careful eye of a microscopy technique  to identify these organisms. But let’s be real: these methods eat up time, take lots of manpower, and chances of mis interpretation of result due to lack of expertise in subject matters.

 That’s where artificial intelligence comes in. With machine learning, deep learning, and big data analytics, AI is changing the game. Now, labs can identify pathogens faster, more accurately, and at a larger scale. In pharma, this isn’t just about speeding things up—it’s a whole new approach to quality control, more predictive and smarter than anything before.

 We’re diving into how AI is used to spot pathogens in pharma settings—looking at how it stacks up against old-school methods, real cases where it’s already working, the hurdles that come with it, and where all this is headed.

 Traditional Methods of Pathogen Identification

 First, let’s check out how things have been done and why those old ways have their limits:

 1. Culture-Based Methods

 Labs grow microbes on special media and identify them based on cultural characterstics. It’s reliable, method but time consuming methods,for results.

 2. Biochemical Testing

 Technician use catalase or oxidase tests, MR/VP test,MR test, Indole Test, Urease Test,Pigment test, Coagulase test. Technicians watch for metabolic reactions 

 3. Microscopy

 Scientists use microscopes to take a look. It’s quick but not always specific, and the results depend heavily on who’s doing the viewing.

 4. Molecular Techniques

 PCR and similar tools are more accurate, but need specialized tools and only work for organisms already catalogued.

 The downsides? These methods take forever, chew up resources, aren’t easy to scale, mistakes slip in, and sometimes unusual bugs slip through undetected.

 How AI Fits into Microbial Identification

 AI covers lots of ground—it’s basically computer systems doing things we’d normally expect from people. In pharma microbiology, these systems are trained on giant pools of data: genetic codes, protein fingerprints, even microscopic images. They learn to spot and classify pathogens as well as (sometimes better than) any human.

 The big AI tools in play:

- Machine Learning: Finds patterns in data and improves as it sees more.

- Deep Learning: Uses neural networks to get into messy stuff like images and genome sequencing.

- Computer Vision: Lets machines analyze microscopic pictures.

- NLP: Sifts through scientific papers and extracts useful info.

 Applications of AI in Pathogen Identification

 1. Image-Based Identification

 AI uses computer vision to analyze microscopic snapshots. Here’s how it works: labs snap digital images, algorithms look for clues—shape, size, stain—and compare them to a library. Results are fast, you don’t need an expert hovering over the microscope, and you get more consistent answers.

 2. Genomic and Metagenomic Analysis

 AI digs into DNA and RNA sequencing, finding pathogens even in complex samples. This lets labs spot new or rare bugs, identify resistance genes, and look at entire mixed microbial communities. AI’s got high sensitivity, picks up stuff that doesn’t grow in a petri dish, and delivers thorough profiles.

 3. Spectroscopy-Based Identification

 With tech like MALDI-TOF, labs pull unique protein signatures from microbes. AI helps interpret these fingerprints, recognizing patterns and sorting organisms. It speeds things up compared to human-led analysis, and it gets better at telling similar species apart.

 4. Predictive Contamination Monitoring

 AI looks at air quality, surfaces, temperature logs, and contamination history. It predicts risks before they become problems, giving labs more control, cutting batch failures, and helping facilities stay in line with regulations.

 5. Automation in Quality Control Labs

 AI teams up with robots and automation systems to streamline everything. Examples include automated sample handling, real-time analysis, and smart support systems. Throughput goes up, hands-on work goes down, and traceability improves.

 Advantages of AI in Pharmaceutical Microbiology

 1. Speed

 Pathogen identification drops from days to hours, even minutes.

 2. Accuracy

 Machine learning gets precise, cutting down on wrong results.

 3. Scalability

 AI tackles huge data sets and sample sizes without breaking a sweat.

 4. Cost Efficiency

 It can be pricey to set up, but automation pays off, trimming labor costs over time.

 5. Continuous Learning

 AI systems keep getting better as they pull in more data.

 Challenges and Limitations

 Adopting AI isn’t easy. Here’s what stands in the way:

 1. Data Quality and Availability

 AI needs loads of good data to learn right. Weak data means unreliable predictions.

 2. Regulatory Compliance

 Pharma’s watched closely, so AI needs validation and transparency to pass muster.

 3. Integration with Existing Systems

 Old systems can be stubborn and don’t always mesh easily with AI.

 4. Interpretability

 Deep learning models sometimes operate like black boxes—you know the answer, but not how it got there.

 5. Cost of Implementation

 Getting started with AI infrastructure and training takes real investment.

 Real World Use Cases

 1. Contamination Detection in Manufacturing

 AI tracks production in real time and flags microbial contamination early.

 2. Rapid Sterility Testing

 AI slashes the time for sterility checks, so products release faster.

 3. Antibiotic Resistance Identification

 AI analyzes genetic patterns to spot resistance, which helps in drug development and treatment plans.

 4. Environmental Monitoring

 Facilities use AI to track trends in cleanroom environments and predict contamination risks.

 Regulatory Considerations

 Agencies like FDA and EMA are warming up to AI in pharma. The big requirements: solid validation, integrity, traceability, clear explanations, and sticking to Good Manufacturing Practices. Systems must keep these checkpoints front-of-mind.

 What’s Next?

 1. Integration with IoT

 AI working with IoT devices means real-time monitoring and smarter decisions.

 2. Personalized Medicine

 AI-powered identification supports custom treatments for individual patients.

 3. Advanced Predictive Analytics

 Future systems will predict outbreaks and contamination—not just detect them.

 4. Cloud-Based AI Platforms

 Data analysis moves to cloud platforms, supporting collaboration across facilities.

 5. Explainable AI (XAI)

 Making AI more transparent helps with regulatory hurdles and builds trust.

 Conclusion

 AI’s changing how pharmaceuticals identify pathogens. It’s making things faster, more accurate, and able to handle more at once. Sure, there are challenges—regulation, data, tech integration—but the pace of innovation and regulators getting onboard means AI’s here to stay.

 Looking ahead, AI won’t just identify pathogens. It will be central to smarter pharmaceutical manufacturing, helping create safer drugs, quicker processes, and much better outcomes for patients.

 Final Thoughts

 The pharmaceutical world sits between responsibility and constant innovation. As AI grows, its role in protecting drug quality and patient health is only getting more important. The organizations jumping into AI-powered microbial identification now are setting themselves up to lead as science keeps moving forward. 

Root Cause Analysis and Remediation of Microbial Contamination during Cleaning Validation Study in Pharmaceutical Industry.

1. Abstract

Background: Cleaning Validation studies is an important aspect in pharmaceutical studies to identify and correct potential problems previously unsuspected, which could compromise the safety, or quality of subsequent batches of product produced within the equipment..

Methods The study was designed as experimental study and conducted between January-June 2025.The study was conducted on Clobetasol 0.05% cream manufacturing equipments. Swabbing technique was used to find microbial load on equipment under the study. Total aerobic Microbial Count (TAMC) 100 cfu/ 100 cm 2 and Total Yeast and Mould Count 10cfu/ 100 cm 2 was set as pass limit during cleaning validation study. Different contamination variables were studied during cleaning validation study.

Result: The mean value of cleaning validation study for Total aerobic Microbial count and Total yeast and mould count was found to be 8.33 and 0.55 for all three batches of used equipments respectively. Standard deviation was found to be 6.08 and 0.511, obtained result was not found statistically significant with respect to p- value <0.05.

Conclusion: Several contamination variables like sanitization technique, frequency of fumigation, access control in area, Microbial load over lint free clot used for mopping was coined during study and after mitigating such contamination variables the study result was found satisfactory. Changed technique like change from chemical method of sterilization to moist heat sterilization of templates , use of lint-free cloths soaked in 70% IPA provided better control, Increased fumigation frequency and limited access in area actc as major preventive measures for contamination Control.

Key Words: Cleaning Validation , Contamination Variables, Findings, Swab technique, Root cause analysis

2. Introduction

Cleaning validation is study done to find the effectiveness and reliability of cleaning pharmaceutical production equipment. People in the pharmaceutical industry use equipment validation and cleaning procedures mainly to prevent cross-contamination that makes these practices crucial. [1] In general, cross-contamination usually happens when an active ingredient from one product is transferred to other product through the instruments improper cleaning that can pose real risks to consumers and second type is contamination by foreign materials, which could be bacteria or fungi .Poor maintenance or storage conditions may let microbes flourish in processing equipment and becomes a serious issue [2]

The most important benefit of conducting cleaning validation work is to identify and correct potential problems previously unsuspected, which could compromise the safety, efficacy or quality of subsequent batches of drug product produced within the equipment. [3]

Cleaning validation guarantees the safety, identity, purity, and strength of products, which are fundamental to cGMP (Current Good Manufacturing Practice) [4]

Significance of Cleaning Validation study

The primary purpose of cleaning validation is to prevent cross-contamination between different pharmaceutical products, thereby ensuring product integrity and patient safety. By verifying the effectiveness of cleaning procedures, it provides assurance that active ingredient or cleaning agent from a previous batch remains under acceptable level on equipment that could not adulterate subsequent products [5].The process typically includes the development of cleaning methods, assessment of worst-case scenarios, establishment of acceptance criteria, and verification using appropriate analytical techniques to quantify residuals and ensure reproducibility [6].

Cleaning Method Development [8,9]

Cleaning method development is a critical component of the pharmaceutical validation lifecycle and is carried out alongside drug development to ensure that cleaning processes are scientifically sound, efficient, and compliant with regulatory expectations. Stages of Cleaning Method Development Cleaning method development typically progresses through three main stages:

1. Feasibility: This stage evaluates whether the proposed method is suitable for the specific sample, equipment, and contaminants in question.

2. Development: Optimization of cleaning parameters such as time, temperature, cleaning agents, and equipment to achieve maximum residue removal.

3. Validation: Demonstration that the optimized cleaning method consistently meets acceptance criteria across multiple runs and conditions

Risk-Based Approach

A risk-based strategy is fundamental in cleaning validation studies. It involves identifying and prioritizing equipment, surfaces, or products that pose a higher risk of contamination or cross-contamination. This approach allows the validation team to focus resources and attention on critical areas where product safety or quality may be most vulnerable. It involves in choosing appropriate cleaning method, test method and justify the result based on regulatory guidelines. Risk-based approaches include Failure Mode and Effects Analysis (FMEA), Fault Tree Analysis (FTA), Hazard Analysis and Critical Control Points (HACCP), and Quantitative Microbiological Risk Assessment (QMRA) [10]

Scope of study

• To study different variables for contamination of clean equipments

• To provide scientific rationale and documentation for cleaning effectiveness.

. To perform cleaning validation study on equipments used for formulation of products

3. Methods

3.0: Study Design

The study was designed as experimental study and conducted between January-June 2025.The study was conducted on Clobetasol 0.05% cream manufacturing equipments in class D manufacturing facility in pharmaceutical Industry. Sampling method was selected as Swabbing technique, to study the microbial load on equipments included the study. Total aerobic Microbial Count (TAMC) 100 cfu/ 100 cm 2 and Total Yeast and Mould Count 10cfu/ 100 cm 2 was set as pass limit during cleaning Validation study. [12].

Study was conducted in 3 phases

a.To study the actual status of microbial load on clean equipments under study

b.To find the different variables for contamination of clean equipments

c.To perform cleaning validation study on equipments used for formulation of products

Test conditions of cleaning validation was designed under static condition .Temperature less (≤ 25 ◦C), and Humidity (≤ 60%) was maintained in sampling areas during study periods. Swabbing technique was used for sampling and membrane filter test method was used for detection of microbial load on equipments included in the study.

3.2: Materials Used under study

Materials and Manufacturer

1 Buffered peptone water: Hi Media

2 Soyabean Casein Digest Agar (SCDA): Hi Media

3 Sabouraud Dextrose Agar (SDA): Hi Media

4 Sterile swab: Hi Media

5 Autoclave: Equitron

6 Bio-safety Cabinet: Thermolab

7 Incubators: Allyone

8 Colony Counter: Lapiz

9.70% IPA: Qualigens

3.3: Sampling Procedure

Test areas of 10 × 10 cm² were measured using sterile stencils. The sterile swabs were moistened with sterile water, and samples were collected from two different 100cm² areas of each piece of clean equipment. A total of two swab samples from each equipment were collected using unidirectional movements—first 10 horizontal Strokes followed by 10 vertical strokes—for the determination of total aerobic microbial count and total yeast and mould count. The swabs were placed into separate test tubes containing 10 mL of Buffered peptone water and transported to the microbiology laboratory.

3.4 Sample analysis and Quality Control

The equipment used during the study was well calibrated. Stencils used for measuring surface area were sterilized in an autoclave at 121 °C and 15 psi for 15 minutes. Soybean Casein Digest Agar was used for the isolation of bacteria, and Sabouraud dextrose agar with chloramphenicol was used for the isolation of fungi. Growth promotion test and Sterility checks of the swab sticks was performed as per USP<61> (United States Pharmacopoeial Convention) 2025[11].

Each tube containing the swab sample was shaken for 2-3 minutes.10 ml of the sample solution was individually pipetted into 50 mL of peptone water, mixed thoroughly, and the entire contents were filtered through a membrane filter with a pore size of 0.45 μm. The membrane filter was aseptically transferred onto Soybean Casein Digest Agar (SCDA) using sterile forceps and incubated at 35 °C for 72 hours. For total yeast and mould count, the filter was placed on Sabouraud Dextrose Agar with chloramphenicol plates and incubated at 25 °C for 5 days [7].

4.0 Result

4.1: Initial Result of cleaning validation study

The load of Microorganism (Total aerobic microbial count) was found out of limit (ie. > 100 Cfu/100cm2) and the total yeast and mould count was found with in pass limit; <10 Cfu/100cm2.. . During the disinfection process of equipments, final rinse was done with purified water. Then 70% IPA was sprayed and mopped with cotton cloth. The result showed that multiple factor may have contributed to the increase bacterial load of on clean equipments under study (Table 1)

Table1: Initial Microbial Load on equipments

S.No.	Equipment	TAMC (Cfu/100cm2) (Limit: <100 cfu)		TYMC (Cfu/100cm2) (Limit: <10 cfu)
		Sampling Location	Result	Sampling Location	Result
1	Wax vessel	From the both side of the baffles (MC-01)	300	From the base of the vessel near discharge(Mc-02)	1
2	Manufacturing Vessel	A sample from the Teflon flanges attached to the homogenizer. (MC-03)	250	A sample from the base of the equipment near the drain pipe(MC-04)	3
3	Storage Vessel/Paste preparation vessel	Sample from the Base on the other (MC-05)	150	Sample from the wall of the vessel (MC-06)	1
4	SS Containers	Wall of the container (MC-07)	180	Base of the container(MC-08)	2
5	SS Jugs	Base of the jugs (MC-09)	200	Base of the jugs(MC-10)	3
6	Semi- Automatic Tube Filling Machine	Inner surface of hopper (MC-11)	240	Surface of the stirrer(MC-12)	4

4.2: Root cause Analysis to find source of contamination

Different variables was selected to find the source of increase microbial load on clean. Test of the total yeast and mould count was excluded in the study as the result was found satisfactory (Table 1)

1. Sample taken without any disinfection process

2. Spray with 70% IPA directly on clean equipment, Air Dry

3. Spray 70% IPA on Lint free cloth and mop the clean equipment

4. Completely dip Lint free Cloth in 70% IPA and Mop the clean equipment

5. Mop the template with 70% IPA and swab taken

6. Lint free cloth soaked in sterile water and mopped the clean equipment

7. Limiting personnel access in the sampling area

8. Decreasing frequency of fumigation in the area

Table 2: Observation of different variables of Study for Microbial load

S.No.	Variables	TAMC (Cfu/100cm2) (Limit: <100 cfu)
1	Sample taken without any disinfection process	190
2	Spray with 70% IPA directly on clean equipment, Air Dry	46
3	Spray 70% IPA on Lint free cloth and mop the clean equipment	330
4	Completely dip Lint free Cloth in 70% IPA and Mop the clean equipment	21
5	Mop the template with 70% IPA and swab taken	10
6	Lint free cloth soaked in sterile water and mopped the clean equipment	1300

The result showed that lint free cloth as main carrier of organism to the clean equipments during clean validation study and also the chemical sanitizing technique of template was not effective.

4.3: Remediation of Microbial Contamination on Clean Equipments

Changed Technique

1. Template sterilization technique was changed from chemical sterilization to moist heat sterilization (Autoclaving)

2. Cloth used for moping was dipped in 70% IPA and Dried before use of final moping on clean equipments.

3. Fumigation frequency in the area was decreased to 3 month to 1 month.

4. Limited access was done in area during sampling in the area.

Table 3: Result after correction of the contamination variables

S.No.	Equipment	Sampling Location	TAMC (Cfu/100cm2) (Limit: <100 cfu)
1	Wax vessel	From the both side of the baffles (Mc-01)	7
2	Manufacturing Vessel	A sample from the Teflon flanges attached to the homogenizer (MC-03)	9
3	Storage Vessel/Paste preparation vessel	Sample from the Base on the other (MC-05)	23
4	SS Containers	Wall of the container (MC-07)	30
5	SS Jugs	Base of the jugs (MC-09)	20
6	Semi- Automatic Tube Filling Machine	Inner surface of hopper (MC-11)	17

After correction of the contamination Variables, the result of Total Aerobic microbial count was found in pass limit < 100 Cfu/100cm2. (Table 3)

Table 4:Cleaning Validation Study Result

S.No.	Equipment	TAMC(cfu/100cm2) (Limit:<100 cfu)				TYMC(cfu/100cm2) (Limit:<10cfu)
		Sampling Location	Result			Sampling Location	Result
			Batch1	Batch2	Batch3		Batch1	Batch2	Batch3
1	Wax vessel	From the both side of the baffles (Mc-01)	7	1	9	From the base of the vessel near discharge (Mc-02)	0	1	0
2	Manufacturing Vessel	A sample from the Teflon flanges attached to the homogenizer .(MC-03)	10	3	2	A sample from the base of the equipment near the drain pipe (MC-04)	1	0	1
3	Storage Vessel/Paste preparation vessel	Sample from the Base on the other (MC-05)	6	3	2	Sample from the wall of the vessel (MC-06)	0	1	1
4	SS Containers	Wall of the container (MC-07)	20	23	14	Base of the container (MC-08)	1	0	1
5	SS Jugs	Base of the jugs (MC-09)	10	12	8	Base of the jugs (MC-10)	0	1	0
6	Semi- Automatic Tube Filling Machine	Inner surface of hopper (MC-11)	5	11	5	Surface of the stirrer (MC-12)	1	0	1
Mean value			8.38			Mean value	0.55
Standard Deviation			6.08			Standard Deviation	0.511

The result of cleaning validation on Clobetasol 0.05% cream manufacturing equipments in class D manufacturing facility in pharmaceutical Industry shows within the acceptance limit below 100 cfu and 10 cfu respectively for Total aerobic microbial count and Total Yeast and Mould count, after correcting the contamination variable. The mean value of Total aerobic Microbial count and Total yeast and mould count was found to be 8.33 and 0.55 for all three batches of used equipments respectively. Standard deviation was found to be 6.08 and 0.511, obtained result was not found statistically significant with respect to p- value <0.05.

Discussion

Cleaning Validation studies is an important aspect in pharmaceutical studies for to identify and correct potential problems previously unsuspected, which could compromise the safety, efficacy or quality of subsequent batches of drug product produced within the equipment. During the study we studied the potential contaminating variables and mitigate the causes to guarantees the safety, identity, purity, and strength of products, which are fundamental to cGMP during formulation of products. Major Root cause of contamination found during study, include technique of sterilization, personnel access in area, duration of Fumigation in area and the carryover of microbial load from lint free cloth to clean equipments during sanitization of equipments.

Conclusion

1. The high Total aerobic microbial count was likely caused by poor sterilization of the sampling tools (Template/Cloth) rather than the equipment cleanliness itself.

2. The change from chemical method of sterilization to moist heat sterilization of templates was critical.

3. The use of lint-free cloths soaked in 70% IPA provided better control.

4. Increased fumigation frequency and limited access improved the environmental control

References

1. Nutan Rao et al. Cleaning validation in pharmaceutical industry, IJRPC 2020, 10(2), 205-214. DOI: https://dx.doi.org/ 10.33289/IJRPC.10.2.2020.10 (39).
2. Kumar et.al. Analytical Method Development and Validation of HPLC Method for the Determination of Fenofibrate in Pharmaceutical Dosage Form (IJARPB), 2012; Vol.2 (2): 154-164. Available online on www.ijarpb.com
3. Parenteral Drug Association. Points to Consider for Cleaning Validation .Technical Report No. 29, 1998.
4. Vinay J G. Department of Pharmaceutical Analysis and QA, Mallareddy College of Pharmacy. Cleaning validation http://www.slideshare.net/vinayjain104 8/cleaningvalidation26237202accessed 22 January 2020.
5. More et. al. Pharmaceutical Cleaning Validation: A Comprehensive Review of Strategies, Regulations, And Analytical Techniques (IJPRA)Volume 10, Issue 4, Jul.-Aug. 2025, pp:537-545 www.ijprajournal.com ISSN: 2456-4494. DOI: 10.35629/4494-1004537545
6. Khan et. al. A review on cleaning validation. Int J Res Pharm Chem. 2020;10(2):205–14.
7. USP<61> (United States Pharmacopoeial Convention) 2025
8. Pharmasubject.com. Cleaning validation bracketing worst case [Internet]. 2016 [cited 2025 Jul 24]. Available from: https://www.pharmasubject.com/2016/09/clea ning-validation-bracketing-worst.htm
9. Fredrick R. The basic facts of cleaning validation. Pharmainfo.net [Internet]. 2004 [cited 2025 Jul 24]. Available from: http://www.pharmainfo.net/reviews/basicfacts-cleaning-validation
10. Singh et al. Risk Based Study of Sample Spot Fixing for Conducting Environmental Monitoring Test in Classified Areas of Pharmaceutical Industry. Int J of Pharm Sci. 2025;3(2):146-52. [https://doi.org/10.5281/zenodo.14793799].
11. Singh SK, Single –time point surface bioburden study at 96 hours dirty hold time study on amlodipine study amlodipine manufacturing equipment in Class D Facility (Non –Sterile). Dale View's Journal of Clinical Pharmacology and Pharmacotherapeutics, Vol. 2 l No. 2 l December 2025
12. IPA, Indian Pharmaceutical Alliance. Retrieved 2023-08-05